| Identification | Back Directory | [Name]
SRT3657 | [CAS]
1383551-17-4 | [Synonyms]
SRT3657
SRT3657,SRT-3657
1-Piperidinecarboxylic acid, 4-[[2-[2-[[[2-butyl-6-[[2-[[(1,1-dimethylethoxy)carbonyl]methylamino]ethyl]amino]-4-pyrimidinyl]carbonyl]amino]phenyl]thiazolo[5,4-b]pyridin-6-yl]methoxy]-, 1,1-dimethylethyl ester | [Molecular Formula]
C40H54N8O6S | [MDL Number]
MFCD34470233 | [MOL File]
1383551-17-4.mol | [Molecular Weight]
774.97 |
| Hazard Information | Back Directory | [Uses]
SRT3657 is a brain-permeable activator of SIRT1, with neuroprotective effect[1]. | [in vivo]
SRT3657 (30 mg/kg; i.g.; daily; for 6 weeks) activates SIRT1 in CK-p25 mice[1].
SRT3657 treatment prevents synaptic and neuronal loss and effectively rescues against neurodegeneration-driven memory impairments[1].
SRT3657 recapitulates the neuroprotective potential of caloric restriction (CR)[1].
| Animal Model: | Adult double-transgenic CK-p25 mice (3-month-old)[1] | | Dosage: | 30 mg/kg | | Administration: | Oral gavage, daily, for 6 weeks | | Result: | Significantly upregulated the activity of SIRT1 in hippocampal extracts of CK-p25 animals. |
| [References]
[1] Gr?ff J, et al. A dietary regimen of caloric restriction or pharmacological activation of SIRT1 to delay the onset of neurodegeneration. J Neurosci. 2013 May 22;33(21):8951-60. DOI:10.1523/JNEUROSCI.5657-12.2013 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|